Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer
Conclusion The combination of Docetaxel, Celecoxib, and Zoledronic acid failed to improve OS or to offer an acceptable biologic response. We do not believe that there is compelling evidence to include either Celecoxib or Zoledronic acid in further phase II/III trials.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Celebrex | Docetaxel | Drugs & Pharmacology | Investigational New Drugs | Neurology | Oral Cancer | Palliative | Palliative Care | Prostate Cancer | Reclast | Study | Taxotere | Toxicology | Zometa